Pharmacophore-guided machine learning and molecular simulations of pyrazole-imine ligands targeting estrogen receptor alpha

Hayder H. Kadhim (), Ayad M.R. Raauf () and Shakir Mahmood A Lwan ()

International Journal of Innovative Research and Scientific Studies, 2025, vol. 8, issue 5, 72-95

Abstract: Estrogen receptor alpha (ERα) plays a crucial role in breast cancer progression, making it a key target for selective estrogen receptor modulators (SERMs). While Raloxifene has demonstrated therapeutic efficacy, resistance and limited bioactivity in some cases necessitate the development of novel ERα inhibitors with improved pharmacological profiles. A computational drug discovery approach integrating molecular docking, molecular dynamics (MD) simulations, and quantitative structure-activity relationship (QSAR) modeling was employed to design and evaluate new ERα inhibitors. Molecular docking was performed using Glide (XP mode) to predict ligand binding affinity and interaction patterns, while MD simulations over 100 ns assessed the stability and conformational dynamics of the protein-ligand complexes. A QSAR model was developed using a dataset of 1,231 compounds from ChEMBL, incorporating XGBoost regression with optimized hyperparameters for robust predictive performance. Compounds 3b, 3a, and 4a showed notable binding affinities (−9.319, −9.121, and −8.867 kcal/mol, respectively) that are comparable to Raloxifene (−9.791 kcal/mol), suggesting their potential as effective ERα ligands primarily through pi-pi stacking with PHE-404 and hydrogen bonding with Glu 353. MD simulations demonstrated that 3a, 4a, and 4b maintained stable receptor interactions (RMSD < 2.0 Å), while 3e and 4e exhibited higher fluctuations, indicating weaker engagement. The QSAR model achieved high predictive accuracy (RMSE < 0.6, R² > 0.8), identifying NO₂ (3d), OMe (3c), and Cl (3b) substitutions as key structural features enhancing receptor binding. This study identifies 3b, 3d, and 4b as promising lead compounds with strong binding affinity, stability, and predicted estrogen receptor activity. These findings provide a basis for further experimental validation and structural refinement to develop next-generation SERMs for ERα-positive breast cancer therapy.

Keywords: Drug discovery; Breast cancer; Estrogen receptor; Molecular docking; Molecular dynamics; QSAR modeling; Selective estrogen receptor modulators (SERMs). (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://ijirss.com/index.php/ijirss/article/view/8570/1934 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:aac:ijirss:v:8:y:2025:i:5:p:72-95:id:8570

Access Statistics for this article

International Journal of Innovative Research and Scientific Studies is currently edited by Natalie Jean

More articles in International Journal of Innovative Research and Scientific Studies from Innovative Research Publishing
Bibliographic data for series maintained by Natalie Jean ().